Cipher Pharmaceuticals ($CPH.TO) FINS Review
Q1 2025
After a rather mediocre end to their 2024 year, I didn’t exactly have Cipher as a must review for Q1. But, the requests out of the new Wolf Den discord were numerous and the Wolf gives the people what they want.
I gave them a rather pedestrian three star review the day after their annuals came out in March. One of my biggest concerns is 74% of their 2024 profits came from income tax recoveries on depleting tax pools, margin issues as well as SG&A costs ballooning so I had big concerns regarding their profitability metrics leading into 2025.
The stock has been on a downwards trend since September. Judging by the market reaction since their financials were released last week, it’s safe to say they were displeased with the share price dropping 11% while the rest of the market has seen a rebound.
Will I feel differently?
Paid Subscriber Benefits:
First access to annual picks, upgrades and mid year picks.
Monthly “What’s Wolf Watching” preview of upcoming earnings and potential market moves.
FinsDontLie Scholastic Series - exclusive educational posts
NEW - Access to The Wolf Den discord community (daily insights, charts, chat & Q&A)